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Abstract
Natural and synthetic immunomodulators that increase non-specific resistance to infection 
induce the production of interleukin-1 (IL-1) and tumor necrosis factor (TNF). Therefore, we 
investigated the effect of IL-1 and of TNF on the survival of lethally-infected mice. Mice were 
injected with 1 x 106 Klebsiella pneumoniae in the thigh muscle. When recombinant human IL-1 ¡3 
was given as a single i.p. injection 24 h before the infection, survival was increased. Using 
80 ng IL-1/? per mouse, survival compared to control animals was 80% versus 20% 48 h after 
the infection (p  <  0.001). No effect of IL-1 was observed when it was given \  h before or 6 h after 
the infection. IL-1 a proved to be at least as potent as IL-1/?,
Numbers of bacteria cultured from the blood, thigh muscle, liver, spleen, and kidney were 
similar in IL-1-treated and control animals. Protection against death by IL-1 was also investi­
gated in granulocytopenic mice with a Pseudomonas aeruginosa infection. Administration o f the 
cyclooxygenase-inhibitor, ibuprofen, did not affect the beneficial effect of IL-1. In this model 
human recombinant TN F was at least tenfold less active than IL-1/?.
Pretreatment with IL-1 also had a significant effect on survival of mice that received a high 
dose of bacterial lipopolysaccharide.
Introduction
Several substances have been shown to in­
crease natural resistance mechanisms [1-6]. 
Most of these substances, such as lipo­
polysaccharide [1-4], BCG, and muramyl 
peptides [5, 6] are derived from bacteria. Be­
cause of their toxicity, these immunomodula­
tory substances have not gained acceptance 
as a therapy in humans.
Substances that increase non-specific resis­
tance appear to be able to stimulate mononu­
clear phagocytes to synthesize and secrete the
cytokines interleukin-1 (IL-1) and tumor 
necrosis factor a (cachectin, TNF) in vitro 
[7,8], IL-1 is the collective name for two 
17 kD proteins (IL-1 /? and a) with a number 
of important biological effects [7, 9]. TN F is 
also a 17 kD protein, which shares many of 
its effects with IL-1 [8, 10, 11]. The main 
difference between the effects of IL-1 and 
TN F is that TN F does not stimulate T 
lymphocytes, whereas IL-1 does. Because 
both IL-1 and TN F are endogenous pyrogens 
and mediate other acute phase responses 
[7-10], it is possible that many of the effects
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of the immunomodulatory substances men­
tioned above are mediated by these mol­
ecules. Therefore, we investigated the ability 
of these cytokines to ameliorate the outcome 
of a lethal infection in mice. In a previous 
study, we investigated the effect of recombi­
nant interleukin-11? on survival of granulocy­
topenic mice with a lethal Pseudomonas 
aeruginosa infection [12]. In that study, we 
found protection with a single low dosage of 
IL-1 /?. It appeared that the animals were only 
protected from death if they were pretreated 
with IL-1 24 h before infection. Although we 
could demonstrate that protection was not 
due to a direct antibacterial effect of IL-1, not 
due to granulocytes and not to activation of 
macrophages, we were unable to elucidate the 
mechanism of protection against lethal P. 
aeruginosa infection. One hypothesis was that 
pretreatment with IL-1 protected against the 
lethal effects of the lipopolysaccharide or 
other toxins of P. aeruginosa.
The present paper deals with a number of 
questions that emerged from these studies: 
(1) Is IL-1 also able to increase survival in 
other lethal Gram-negative infections? (2) 
Does IL-1 protect against death due to bacte­
rial lipopolysaccharide? (3) Is recombinant 
human TNF also able to increase survival of 
granulocytopenic mice with a lethal Pseu­
domonas aeruginosa infection?
Materials and methods
Mice. Female, 25 g Swiss Webster mice 
(Taconic Farms, Germantown NY and 
Broekman, Someren, the Netherlands), were 
fed standard lab chow and water ad libitum.
IL-1 and TNF. Recombinant human IL-1/? 
(kindly supplied by Cistron Biotechnology, 
Pine Brook, NJ), which contains less than 
30 pg of endotoxin per mg of protein, was 
used in the majority of the experiments. Re­
combinant IL-1/? from a different source 
(kindly provided by Dr Alan Shaw, Biogen/
Glaxo, Geneva, Switzerland) and recombi­
nant human IL-1 a (kindly provided by Dr 
Peter Lomedico, Hoffmann La Roche, Nut- 
ley, NY) were also used. Recombinant hu­
man TNFa containing less than 30 pg 
endotoxin per mg of protein was provided by 
Genetech Inc., South San Francisco.
IL-1 and TN F were given as a single i.p. 
injection in 2% (vol/vol) normal mouse 
serum in 0.1 ml pyrogen-free saline. Control 
mice received heat-inactivated IL-1 (100°C 
for 20min).
Infection models. Klebsiella pneumoniae 
(ATCC 43816), a strain which produces a 
lethal infection in normal mice [ 13], was inoc­
ulated in the left thigh muscle of non-neu- 
tropenic mice as described elsewhere [14]. 
Unless stated otherwise an inoculum of 
1 x 106 was used. The mice in each cage were 
randomized to receive either IL-1 at different 
time points, or heat-inactivated IL-1. Survival 
was scored over a period of at least 48 h.
For the Pseudomonas aeruginosa infection 
mice were rendered granulocytopenic 
(<0.5 x 109 granulocytes per liter) by means 
of two i.p. injections of cyclophosphamide 
(Bristol Myers, Syracuse, NY), 150 and 
100 mg/kg of body weight, respectively, 4 
days and 1 day before the inoculation of the 
microorganism. Between 1 x 107 and 1 x 10s 
Pseudomonas aeruginosa (ATCC27853) were 
injected into the left thigh muscle. Two doses 
of gentamicin (Lyomed Inc., Rosemont, IL), 
120 mg/kg, were given s.c., 6 and 23 h post 
infection. In one series of experiments, mice 
were pretreated with a single subcutaneous 
injection of 10 mg/kg of the cyclooxygenase 
inhibitor ibuprofen (Upjohn Co, Kalamazoo, 
MI) 24 h before the infection.
Clearance o f bacteria. Twenty-four hours after 
the injection of Klebsiella pneumoniae, mice 
were killed by C 0 2 asphyxia. Immediately 
after death, blood cultures were taken by 
cardiac puncture, and the muscles of the left 
thigh (the site of inoculation of the bacteria),
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the spleen, the kidney and the liver were 
removed aseptically, weighed and homoge­
nized in sterile saline in a tissue grinder. To 
bring the counts into the optimal range for 
reading, samples of thigh muscle were diluted 
1: 104 and other samples were diluted 1:10 in 
sterile saline. The suspensions were then 
plated on sterile Mueller-Hinton agar using 
the automated spiral plater (Spiral Systems 
Inc, Cincinnati, OH) as described elsewhere 
[12]. After overnight incubation at 37°C, the 
number of cfu was counted.
Death due to bacterial endotoxin. A single 
intraperitoneal injection of 800 fig of E. coli 
endotoxin (lipopolysaccharide, Sigma, St 
Louis, MI) was given to mice 24 h after the 
administration of 80 ng IL-1/? i.p. or heat 
inactivated IL-1 i.p. Survival was scored.
Statistical analysis. Survival curves were 
analysed using the Kaplan Meier/log rank 
test [15].
Results
The effect o f IL-1 in Klebsiella pneumoniae 
infection
The rate of death of non-neutropenic outbred 
Swiss mice infected with K. pneumoniae in the 
thigh muscle is greatly dependent on the in­
oculum. With 1 x 106 cfu approximately 80% 
of the control mice would die within 48 h. 
Higher inocula resulted in accelerated death.
Recombinant human IL-1/?, given as a sin­
gle i.p. injection of 80 ng (which equals 3 jug/ 
kg) 24 h before infection, improved the 
survival of these mice significantly compared 
to mice that received heat-inactivated IL-ly3 
(Fig. 1). When IL-1 was given shortly before 
injection of K. pneumoniae, survival was not 
significantly better than in the control group 
(Fig. 1). IL-1 given as late as 6 h after the 
inoculation of the bacteria also failed to im­
prove survival (data not shown). The results
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Fig. 1. T he effect o f  IL-1 /3 trea tm en t on the survival o f  mice 
w ith a Klebsiella pneum oniae  infection . R eco m b in an t h u m an  
IL-ljS was given as a  single i.p. in jection  either 24 h o r 30 m in 
before the in tram u scu la r inocu la tion  o f  1 x 106 bacteria  in the 
thigh muscle. C o n tro l m ice received h eat-inactiva ted  IL-1 
(100°C for 20 m in). There were a t least 30 m ice in each  group. 
T he difference in survival betw een the  g roup  th a t received 
IL-1 24 h before infection  an d  the co n tro l g roup  is significant 
a t p  < 0 .0 1 . Survival o f  the g ro u p  th a t received IL-1 30 m in 
before infection does n o t differ fro m  th a t o f  the con tro ls.
obtained with recom binant IL-1/? from the 
two sources were similar. IL-1 a proved to be 
as least as potent as IL-1/? (data not shown).
Clearance o f  K. pneumoniae
No differences in the numbers of bacteria in 
blood and tissues were found between mice 
treated with IL-1 or with heat-inactivated 
IL-1 24 h after an intramuscular injection of 
1 x 106 K. pneumoniae (Fig. 2). When the data 
were expressed as number of microorganisms 
per organ rather than per gram of tissue, the 
data from two groups also did not differ.
The effect o f  ibuprofen on the protection by 
IL-1
Pretreatment with a single injection of ibupro­
fen 30 min before the injection of IL-1 did not 
significantly influence the survival of either the 
IL-1 treated mice or the control mice. A 
representative experiment in granulocytopenic 
mice inoculated with P. aeruginosa is shown in 
Fig. 3.
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Fig. 2. C ounts o f colonies of Klebsiella pneumoniae in the blood 
and organs o f  mice 24 h after an intramuscular injection o f 
1 x 106 cfu o f  K. pneumoniae. Mice received either 80 ng human 
recom binant IL-1/Ï o r heat-inactivated IL -l/i 24 h before infec­
tion. Each b ar represents the mean +  standard error o f  log cfu/g 
tissue in 6 mice.
The effect o f IL-1 on endotoxin-mediated 
death
Mice pretreated with IL-1/?, 24 h before an 
injection with a LD70 dose of endotoxin 
(800 fig) showed significantly greater survival 
than mice pretreated with heat-inactivated 
IL-1 (Fig. 4).
Comparison o f TNF and IL-1 in Pseudomonas 
infection
Pretreatment with a dose of 80 ng TNF, 24 h 
before infection did not increase survival of 
neutropenic mice with a lethal P. aeruginosa 
infection, whereas the same dose of IL-1/? 
did. A representative experiment is shown in 
Fig. 5. A tenfold higher dose of TNF did 
increase survival, although not to the same 
extent as 80 ng IL-1 (Fig. 5). A combination 
of 8 ng TNF and 8 ng IL-1/? did not influence 
survival (data not shown).
Discussion
In these studies, we report the efficacy of a 
low dose of IL-1/? and IL-1 a (3.0 fig/kg) in 
prolonging survival in mice with a lethal 
Klebsiella pneumoniae infection. These studies 
expand on the results we obtained in granulo-
Hr-.
Fig. 3. The effect o f  pretrea tm ent with a single injection of 
ibuprofen on the  survival o f granulocytopenic mice treated with 
either 80 ng IL-1/) or heat inactivated IL-1 24 h before infection 
with 1 x 107 cfu P. aeruginosa. T he differences between the mice 
tha t received active IL-1 and those that did not are significant 
(p  <  0.05). E ach  group consists o f 12 mice.
cytopenic mice with a lethal Pseudomonas 
aeruginosa infection [12] and on the results, 
recently reported by Ozaki et al. [16]. These 
investigators also found increased resistance 
to infection using human recombinant IL-1 a 
in non-neutropenic mice that were infected 
with either P. aeruginosa or Klebsiella pneu­
moniae. Increased resistance to infection has
H rs
Fig. 4. The effect of treatm ent w ith 80 ng IL -1/3 at - 2 4  h  ( ■ )  
on death induced by in traperitoneal injection of 800 ¡ig E, coll 
lipopolysaccharide in mice, C ontro l mice ( □ )  received heat in­
activated IL-1. The differences between the two groups, each o f  
which consisting o f 35 mice, are significant (p  < 0.05).
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Fig. S. C om parison  o f  the effect o f  T N F  and IL -lp  on  survival 
of granulocytopenic mice infected with 5 x 107 P. aeruginosa. 
Each g roup  consists o f  11 mice.
been induced with IL-1 in other experimental 
models with facultative intracellular bacteria. 
Czuprynski and Brown have protected mice 
from lethal infection with Listeria monocyto­
genes with recombinant IL-1 [17], and many 
years ago Pulliam and Kampfschmidt have 
reported increased survival of rats infected 
with Salmonella typhimurium, using partially 
purified IL-1 [18].
Like in our previous studies with P. aerugi­
nosa, the time of administration of IL-1 in 
relation to the time of Klebsiella infection in 
the present study was crucial. The lack of a 
beneficial effect when IL-1 is given shortly 
before infection might be explained by the 
rapidity of the spread of these Gram-negative 
bacteria in mice. Recent experiments with 
Candida albicans in granulocytopenic mice 
show that IL-1 is effective when given as late 
as 6 h after infection [19].
Our experiments using TNF show that a 
low dose of recombinant human TNF does 
not protect against death from P. aeruginosa, 
whereas a tenfold higher dose (800 ng per 
mice, which equals 30 ¿¿g/kg) does to some 
extent. Similar findings were reported by 
Parant, who used different infection models 
[20, 21], Taverne et al. have demonstrated 
that recombinant mouse TNF at dosages as
high as 5-10 ng  per mouse increased survival 
and reduced parasitemia in experimental 
malaria [22].
Why TNF was less potent in our studies 
than IL-1 is presently unclear. One explana­
tion could be that it is due to the suboptimal 
fit of human TN F in murine T N F  receptors 
[23], a problem which does not seem to exist 
for IL-1. It is also o f interest that we did not 
find synergism between IL-1 and TN F, since 
synergistic effects o f these cytokines have 
been described in a variety of conditions in 
vitro and in vivo [24-26].
The mechanisms responsible for the cy- 
tokine-induced increase in survival remain 
unclear. In our previous studies a direct anti­
bacterial effect of IL-1 was ruled out in vitro 
[12]. Because the mice were profoundly gran­
ulocytopenic in those studies, an effect of 
IL-1 on the neutrophils was considered un­
likely. Also, the beneficial effects of IL-1 on 
hematopoiesis [27, 28] were not dem onstrated 
in our short-term experiments [12]; the 
present experiments in norm al mice further 
argue against such a mechanism as the expla­
nation.
An effect of IL-1 on macrophages could 
also not be demonstrated [12]. The most con­
vincing argument against an effect on 
macrophage activation came from the bacte­
rial clearance data, which failed to dem on­
strate a difference between IL-1-treated and 
control mice. In the present study, we have 
obtained similar results with K. pneumoniae in 
non-neutropenic mice, i.e., the numbers of 
bacteria in the blood and the various organs 
were similar in IL-1-treated mice and control 
mice.
We have previously speculated that a hu­
moral factor, for example an acute phase 
protein, such as an endotoxin-binding protein 
[29, 30] could be responsible for protection. 
Although we presently report a certain degree 
of tolerance against endotoxin, we have ob­
tained other data that refute such a hum oral 
factor as the mechanism o f protection. First, 
we have recently demonstrated tha t IL-1 gives
24
considerable protection in lethal infection with 
Candida albicans, a microorganism that does 
not contain endotoxin [19]. Secondly we were 
unable to provide protection against C. albi­
cans or P. aeruginosa by passive transfer of 
serum.
It is assumed that cytokines like TNF and 
IL-1 contribute to death from infection 
[25, 31, 32], It could well be that early treat­
ment with IL-1 (and TNF) reduces the lethal 
effects of these cytokines. Since bacterial endo­
toxin is one of the most potent inducers of 
these cytokines, the endotoxin tolerance in­
duced IL-1, could fit in such a concept. Inter­
estingly, two other favorable effects of IL-1 
treatment in experimental animals, namely 
protection from lethal radiation [33] and pro­
tection against oxygen damage [26], are also 
presently unexplained, but could depend on 
similar mechanisms.
In conclusion, our studies and those of 
others demonstrate that IL-l/J and IL-la and 
to a lesser extent TNF are able to increase 
natural resistance to infection. Although the 
mechanism of protection is not understood, 
these results hold promise for the treatment of 
infections in humans, especially in neutropenic 
patients. A dose of IL-1 of 3 jag/kg (which 
equals 1.2 mg/m2) is highly protective. Similar 
dosages of TN F are presently given to humans 
in phase 1/phase 2 studies. If one assumes that 
IL-1 is somewhat less toxic than TNF, treat­
ment with the former cytokine should be 
feasible. Since the protective effect of IL-1 is 
not blocked by ibuprofen, premedication with 
a cyclooxygenase inhibitor could probably 
prevent a large number of side effects.
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